Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Mosquito-Borne Diseases

ClinicalTrials.gov lists 1,936 trials for Mosquito-Borne Diseases or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 180.

MeSH D000096724 Infections C01
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 377 Phase 1/2 Phase 1/2 84 Phase 2 Phase 2 240 Phase 2/3 Phase 2/3 43 Phase 3 Phase 3 255 Phase 4 Phase 4 229 Not applicable Not applicable 346 Observational Observational 360 Phase 1 Phase 1 377 Phase 1/2 Phase 1/2 84 Phase 2 Phase 2 240 Phase 2/3 Phase 2/3 43 Phase 3 Phase 3 255 Phase 4 Phase 4 229 Not applicable Not applicable 346 Observational Observational 360

Trials per phase

2 more sections with rows

6 of the 1,936 trials are tagged with Mosquito-Borne Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Mosquito-Borne Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Mosquito-Borne Diseases trials start? (32)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 7 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 129

1993: 1 trials (Phase 4 1) 1995: 1 trials (Not applicable 1) 1997: 1 trials (Phase 2 1) 1998: 3 trials (Observational 1, Not applicable 1, Phase 2 1) 1999: 2 trials (Not applicable 1, Phase 1 1) 2000: 6 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 2) 2001: 9 trials (Not applicable 1, Phase 4 4, Phase 3 2, Phase 2 1, Phase 1/2 1) 2002: 24 trials (Observational 2, Not applicable 6, Phase 4 6, Phase 3 4, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 1) 2003: 33 trials (Not applicable 5, Phase 4 8, Phase 3 9, Phase 2/3 2, Phase 2 4, Phase 1/2 2, Phase 1 3) 2004: 44 trials (Observational 4, Not applicable 7, Phase 4 3, Phase 3 10, Phase 2/3 4, Phase 2 5, Phase 1/2 4, Phase 1 7) 2005: 72 trials (Observational 9, Not applicable 9, Phase 4 11, Phase 3 13, Phase 2/3 2, Phase 2 11, Phase 1/2 3, Phase 1 14) 2006: 82 trials (Observational 15, Not applicable 10, Phase 4 8, Phase 3 12, Phase 2 17, Phase 1/2 7, Phase 1 13) 2007: 72 trials (Observational 10, Not applicable 6, Phase 4 13, Phase 3 14, Phase 2/3 3, Phase 2 12, Phase 1/2 1, Phase 1 13) 2008: 60 trials (Observational 9, Not applicable 9, Phase 4 8, Phase 3 8, Phase 2/3 2, Phase 2 13, Phase 1/2 2, Phase 1 9) 2009: 70 trials (Observational 8, Not applicable 10, Phase 4 11, Phase 3 9, Phase 2/3 1, Phase 2 9, Phase 1/2 3, Phase 1 19) 2010: 101 trials (Observational 23, Not applicable 16, Phase 4 11, Phase 3 20, Phase 2/3 3, Phase 2 5, Phase 1/2 4, Phase 1 19) 2011: 79 trials (Observational 11, Not applicable 14, Phase 4 11, Phase 3 16, Phase 2 8, Phase 1/2 5, Phase 1 14) 2012: 75 trials (Observational 9, Not applicable 16, Phase 4 12, Phase 3 8, Phase 2/3 1, Phase 2 5, Phase 1/2 6, Phase 1 18) 2013: 77 trials (Observational 11, Not applicable 14, Phase 4 12, Phase 3 9, Phase 2/3 1, Phase 2 10, Phase 1/2 5, Phase 1 15) 2014: 87 trials (Observational 10, Not applicable 19, Phase 4 14, Phase 3 8, Phase 2/3 5, Phase 2 9, Phase 1/2 2, Phase 1 20) 2015: 88 trials (Observational 17, Not applicable 14, Phase 4 10, Phase 3 8, Phase 2/3 4, Phase 2 7, Phase 1/2 6, Phase 1 22) 2016: 129 trials (Observational 38, Not applicable 19, Phase 4 8, Phase 3 12, Phase 2 12, Phase 1/2 8, Phase 1 32) 2017: 74 trials (Observational 18, Not applicable 11, Phase 4 7, Phase 3 8, Phase 2 11, Phase 1/2 2, Phase 1 17) 2018: 91 trials (Observational 22, Not applicable 16, Phase 4 6, Phase 3 12, Phase 2 12, Phase 1/2 2, Phase 1 21) 2019: 70 trials (Observational 13, Not applicable 13, Phase 4 6, Phase 3 8, Phase 2/3 2, Phase 2 11, Phase 1/2 4, Phase 1 13) 2020: 72 trials (Observational 21, Not applicable 17, Phase 4 5, Phase 3 7, Phase 2/3 1, Phase 2 2, Phase 1/2 3, Phase 1 16) 2021: 99 trials (Observational 24, Not applicable 22, Phase 4 8, Phase 3 14, Phase 2/3 2, Phase 2 13, Phase 1/2 1, Phase 1 15) 2022: 85 trials (Other 1, Observational 16, Not applicable 19, Phase 4 10, Phase 3 8, Phase 2 12, Phase 1/2 2, Phase 1 17) 2023: 79 trials (Observational 17, Not applicable 19, Phase 4 8, Phase 3 5, Phase 2/3 2, Phase 2 9, Phase 1/2 5, Phase 1 14) 2024: 78 trials (Observational 20, Not applicable 17, Phase 4 9, Phase 3 10, Phase 2/3 1, Phase 2 9, Phase 1/2 2, Phase 1 10) 2025: 85 trials (Observational 20, Not applicable 16, Phase 4 9, Phase 3 10, Phase 2/3 2, Phase 2 10, Phase 1/2 3, Phase 1 15)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 66
2025 85
2024 78
2023 79
2022 85
2021 99
2020 72
2019 70
2018 91
2017 74

Showing 10 of 32 earlier years.

Start your 14-day trial Email me all 32 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 83 trials starting in 2026 and about 78 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 35 months from start to primary completion across 93 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 1,393 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Mosquito-Borne Diseases trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 377
Phase 1/2 84
Phase 2 240
Phase 2/3 43
Phase 3 255
Phase 4 229
Not applicable 346
Observational 360
Expanded access 1
Unknown 1

How many Mosquito-Borne Diseases trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 56
Recruiting 95
Enrolling by invitation 7
Active, not recruiting 53
Completed 1,411

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Mosquito-Borne Diseases trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 180
U.S. Army Medical Research and Development Command 62
GlaxoSmithKline 56
Sanofi Pasteur, a Sanofi Company 49
Centers for Disease Control and Prevention 37

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Mosquito-Borne Diseases? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Chloroquine 69
Primaquine 67
Tafenoquine 26
Yellow Fever Vaccine 26
Coartem 21

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
1. Artemether-Lumefantrine (AL) 89
Dihydroartemisinine-Piperaquine 81
Pyrimethamine/sulfadoxine 47
Artesunate 38
PfSPZ (7G8) Challenge 28

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Mosquito-Borne Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Malaria 1,964 30
Pneumonia 1,864 60
Gastroenteritis 1,689 54
Febrile convulsion 1,055 28
Anaemia 1,047 20

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Mosquito-Borne Diseases? (1)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases. The New England journal of medicine 2025 Yes

Sub-conditions in MeSH (8)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages